Chronicle Journal: Finance

Goldman thinks the market is underestimating the odds of a faster-than-expected coronavirus vaccine

Markets underappreciate the odds of an early Covid-19 vaccine and the chances of an FDA approval by the end of November, Goldman Sachs says.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.